Management of Genitourinary Infections During SGLT2i Use

Prevalence and Risk Factors

• Genital mycotic infections occur in approximately 6% of patients on SGLT2i therapy compared to 1% in those on placebo 1

Prevention Strategies

• Counsel patients on proper genital hygiene before and during SGLT2i therapy 2
• Educate patients about early symptoms of genitourinary infections to facilitate prompt treatment 1, 3

Management Algorithm for Genitourinary Infections

• Treat most genital mycotic infections with standard antifungal therapy 1
• Continue SGLT2i therapy during treatment of mild to moderate infections 1, 3
• Consider temporary discontinuation of SGLT2i in severe or recurrent UTIs 3
• Resume SGLT2i after complete resolution of the infection 3
• Discontinue SGLT2i immediately for severe infections or Fournier's gangrene 1
• Provide urgent medical attention and appropriate surgical and antibiotic management 1
• Consider permanent discontinuation of SGLT2i in cases of severe or recurrent infections 3

Special Considerations

• Immunocompromised patients, including kidney transplant recipients, may be at higher risk for infections and require more careful monitoring 1, 3
• Patients with Type 1 diabetes may have different risk profiles for infections compared to those with Type 2 diabetes 1
• Consider withholding SGLT2i during periods of acute illness, prolonged fasting, or surgery when patients may be at greater risk for complications 4, 3

Follow-up Recommendations

• Monitor patients for symptoms of genitourinary infections during routine follow-up visits 2
• Reassess the risk-benefit ratio of continuing SGLT2i therapy in patients with recurrent infections 3

Common Pitfalls and Caveats

• Do not confuse euglycemic ketoacidosis with symptoms of genitourinary infection 1
• Severe cases of Fournier's gangrene require immediate medical attention 1, 5
• Maintain at least low-dose insulin in insulin-requiring individuals to mitigate the risk of ketoacidosis 2
• The benefits of SGLT2i on kidney and cardiovascular outcomes generally outweigh the risk of genitourinary infections in most patients 4, 6

SGLT2 Inhibitors and Genital Mycotic Infections

Comparison and Clinical Decision Making

• Current guidelines and research do not identify significant differences in the rates of genital mycotic infections between empagliflozin, dapagliflozin, and canagliflozin, according to Pharmacology and Therapeutics 7, 8
• The selection of SGLT2 inhibitors should be based on cardiovascular risk, comorbidities, and patient sex, as recommended by Pharmacology and Therapeutics 7
• Consider the patient's overall risk profile, including history of prior genital infections, when selecting an antidiabetic agent, as suggested by Pharmacology and Therapeutics 8

Special Considerations

• Severe cases like Fournier's gangrene, while rare, require immediate medical attention, as stated by the Journal of the American College of Cardiology 9

Management of SGLT2‑Inhibitor–Associated Genitourinary Risks

Infection Risk Profile

• Genital mycotic infections occur more frequently with SGLT2 inhibitors (approximately 6 % of users vs 1 % with placebo), representing the principal genitourinary adverse event rather than urinary‑tract infections. 10

Alternative Antihyperglycemic Therapies

• GLP‑1 receptor agonists (e.g., dulaglutide, liraglutide, semaglutide) can be used without dose adjustment and provide cardiovascular benefit while not increasing urinary‑tract infection risk. 10
• Metformin remains appropriate when estimated glomerular filtration rate (eGFR) is ≥ 30 mL/min/1.73 m²; if eGFR is 30–44 mL/min/1.73 m², the dose should be reduced to roughly 1000 mg per day. 10
• DPP‑4 inhibitors such as linagliptin require no dose adjustment in renal impairment and constitute a safe alternative to SGLT2 inhibitors. 10

Prevention and Management Strategies

• Patients should receive counseling on proper genital hygiene and adequate hydration to lower the risk of genital infections while on SGLT2 inhibitors. 11
• For individuals who require insulin, maintaining at least a low‑dose insulin regimen helps mitigate the risk of euglycemic ketoacidosis when an SGLT2 inhibitor is continued. [11][10]
• It is advisable to withhold SGLT2 inhibitors during periods of acute illness, prolonged fasting, or before surgical procedures to reduce the likelihood of adverse events. 11

Guideline Recommendations

• In adults with chronic kidney disease (eGFR ≥ 20 mL/min/1.73 m² with albuminuria ≥ 200 mg/g) or with heart failure, a strong (Class 1, Level A) recommendation supports continued SGLT2‑inhibitor therapy; infection risk alone rarely justifies permanent discontinuation. 11

Management of Genital Candidiasis in Patients Treated with Empagliflozin

Treatment of Active Episodes

• Oral fluconazole 150 mg as a single dose provides >90 % clinical cure for uncomplicated vulvovaginal candidiasis in patients receiving empagliflozin. 12
• Topical azole creams (e.g., clotrimazole, miconazole, terconazole) applied intravaginally for 3–7 days are equally effective as oral fluconazole for these infections. 12

Strategies for Recurrent Infections (≥ 4 Episodes/Year)

• Induction therapy: a 10–14‑day course of either topical azole or oral fluconazole is recommended to achieve rapid symptom control in recurrent cases. [Citation 12]
• Maintenance therapy: after induction, weekly fluconazole 150 mg for 6 months maintains symptom control in >90 % of patients. [Citation 12]
• Post‑maintenance expectation: despite successful maintenance, 40–50 % of patients experience another episode within the following year, prompting reassessment of empagliflozin continuation. [Citation 12]
• Temporary empagliflozin hold: consider holding the SGLT2 inhibitor when recurrent infections (≥ 4 episodes/yr) markedly impair quality of life. [Citation 12]

Recognition of Serious Complications

• Fournier’s gangrene (necrotizing fasciitis of the perineum) constitutes a medical emergency; immediate discontinuation of empagliflozin, urgent surgical debridement, and broad‑spectrum antibiotics are required. [Citation 13]

Balancing Cardiovascular Benefits Against Infection Risk

• Empagliflozin delivers a 35 % relative reduction in heart‑failure hospitalizations, reflecting substantial cardiovascular mortality benefit that must be weighed against the burden of genital mycotic infections. [Citation 14]